

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



山東新華製藥股份有限公司

Shandong Xinhua Pharmaceutical Company Limited

(a joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 0719)

CLARIFICATION ANNOUNCEMENT REVISED PROXY FORM

Reference is made to the proxy form regarding the class meeting of the shareholders of H shares for 2015 (the “**H Shareholders Class Meeting**”) dated 12 November 2015 (the “**Original Proxy Form**”) of Shandong Xinhua Pharmaceutical Company Limited (the “**Company**”).

Unless otherwise specified, capitalised terms used in this announcement shall have the same meanings as defined in the H Shareholders Class Meeting Proxy Form.

The Board of the Company hereby clarify that, due to inadvertent typographical error, special resolution item 1.11, namely, “Effective period of the shareholders’ resolutions;” has not been included in the Chinese version of the Original Proxy Form.

The English version of the Original Proxy Form does not carry this typographical error.

For that reason, printed copies of the revised form of proxy (the “**Revised Proxy Form**”) will be despatched to the shareholders of the Company as soon as practicable. The Revised Proxy Form will also be available on the website of the Company and The Stock Exchange of Hong Kong Limited.

The date, time and venue for holding the H Shareholders Class Meeting remain unchanged.

Whether or not you are able to attend the H Shareholders Class Meeting, you are required to complete and return the Revised Proxy Form in accordance with the instructions printed thereon as soon as possible and in any event not less than 24 hours before the time appointed for holding the H Shareholders Class Meeting or any adjournment thereof (as the case may be).

Please note that the Revised Proxy Form supersedes and replaces the Original Proxy Form.

A shareholder who has not yet lodged the Original Proxy Form with the company secretary’s office of the Company is required to lodge the Revised Proxy Form if he or she wishes to appoint proxies to attend the H Shareholders Class Meeting on his or her behalf. In this case, the Original Proxy Form should NOT be lodged with the company secretary’s office of the Company.

Shareholders who have signed and returned the Original Proxy Form should sign and return the Revised Proxy Form in accordance with the instructions printed thereon.

If the Revised Proxy Form is not signed and returned after the Original Proxy Form has been signed and returned, the Original Proxy Form will remain valid and effective to the fullest extent applicable, if correctly completed.

Shareholders are reminded that completion and delivery of the Original Proxy Form, and/or the Revised Proxy Form will not preclude the shareholders from attending and voting in person at the H Shareholders Class Meeting or at any adjourned meeting thereof should they so wish.

This announcement is published for clarification purposes and we apologize to the shareholders for any inconvenience caused.

By Order of the Board

Shandong Xinhua Pharmaceutical Company Limited

Zhang Daiming
Chairman

23 November 2015, Zibo, the People's Republic of China

As at the date of this announcement, the Board comprises:

Executive Directors:

Mr. Zhang Daiming (Chairman)
Mr. Du Deping

Independent Non-executive Directors:

Mr. Du Guanhua
Mr. Li Wenming
Mr. Chan Chung Kik, Lewis

Non-executive Directors:

Mr. Ren Fulong
Mr. Xu Lie
Mr. Zhao Bin